ClinicalTrials.gg

Program

HRS-5041

A development code. Also written as “HRS-5041 Single dose of HRS-5041 orally administered”, “HRS-5041 tablets” and “HRS-5041 Tablets”.

In Jiangsu HengRui Medicine's pipeline, AR PROTAC. Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Aug 21, 20246 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine53 open or runningphase 2since Aug 21, 2024Jul 5, 2023Dec 2026phase 2 · NCT06568094
Hansoh Pharmaceutical Group11 open or runningphase 1since Aug 4, 2025Aug 4, 2025Dec 2027phase 1 · NCT07115446
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5041, phase 2, as of Jul 31, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 5, 2023First study: phase 1 study in Advanced Prostate CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05942001 · 100 planned · China
  2. Aug 2, 2024Phase 1 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06559007 · 24 enrolled · Australia
  3. Aug 21, 2024Phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094 · 100 planned · China
  4. Feb 12, 2025Phase 1 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT06830850 · 25 enrolled · Australia
  5. Jun 3, 2025Phase 1 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT07014488 · 16 enrolled · China
  6. Aug 4, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Advanced Prostate CancerNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07115446 · 63 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Prostatic NeoplasmsJiangsu HengRui Medicine · NCT06568094
  2. Dec 30, 2026Primary completion: phase 1 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT06830850
  3. Dec 2027Primary completion: phase 1 study in Advanced Prostate CancerHansoh Pharmaceutical Group · NCT07115446

TargetBeta

“AR PROTAC”the company's pipeline, read by Claude · source
“HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors.”study summary, read by Claude · the study

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07115446Advanced Prostate Cancer · China1RecruitingHansoh Pharmaceutical GroupDec 202763
NCT07014488Prostatic Neoplasms · China1CompletedJiangsu HengRui MedicineAug 1, 202516
NCT06830850Metastatic Castration Resistant Prostate Cancer · Australia1Active, not recruitingJiangsu HengRui MedicineDec 30, 202625
NCT06568094Prostatic Neoplasms · China2RecruitingJiangsu HengRui MedicineDec 2026100
NCT06559007Prostatic Neoplasms · Australia1CompletedJiangsu HengRui MedicineJan 6, 202524
NCT05942001Advanced Prostate Cancer · China1RecruitingJiangsu HengRui MedicineSep 2026100

How it is read

Names in the registry

  • “HRS-5041”, 2 entries
  • “HRS-5041 Single dose of HRS-5041 orally administered”, 1 entry
  • “HRS-5041 tablets”, 1 entry
  • “HRS-5041 Tablets”, 1 entry
  • “HRS-5041 dose level 1”, 1 entry

Codes read as this program: HRS5041.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.